Patent ID: 11919961
Assignee: CELLECTIS
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 0:
1. An ex vivo method of engineering a T cell suitable for an allogenic immunotherapy treatment of a pre-malignant or malignant cancer condition characterized by CD123-expressing cells, the method comprising:
(a) providing a T cell;
(b) inactivating at least one gene encoding one or more components of a T-cell receptor (TCR) in the T cell;
(c) introducing into the T cell at least one polynucleotide encoding a CD123 specific chimeric antigen receptor (CAR) to be expressed at the surface of the cell;
wherein the CD123 specific CAR comprises an extracellular ligand binding domain comprising a heavy chain variable region (VH) and a light chain variable region (VL) from a monoclonal anti-CD123 antibody, wherein the VH region comprises CDR sequences set forth in SEQ ID NOs: 67, 68, and 69, and wherein the VL region comprises CDR sequences set forth in SEQ ID NOs: 70, 71, and 72; an FcγRIIIα, CD8a, or IgG1 hinge; a CD8α transmembrane domain; and a cytoplasmic domain comprising a CD3-ζ signaling domain and a co-stimulatory domain from 4-1BB.